Status:
TERMINATED
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
Lead Sponsor:
AstraZeneca
Conditions:
Lymphoma
NHL
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study has two parts (A and B). The primary purpose of Part A is to find the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients tha...
Eligibility Criteria
Inclusion
- Part A: Advanced solid tumors (including lymphoma without bone marrow involvement) for which standard treatment doesn't exist or is no longer effective.
- Part B: B-cell non-Hodgkin lymphoma that is not eligible for curative therapy or has relapsed.
- Relatively good overall health other than your cancer
Exclusion
- Poor bone marrow function (not producing enough blood cells). Serious heart conditions. Poor liver or kidney function
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2008
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00471367
Start Date
April 1 2007
End Date
December 1 2008
Last Update
September 24 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
New York, New York, United States
2
Research Site
Philadelphia, Pennsylvania, United States
3
Research Site
Greenville, South Carolina, United States